AGL (28) PARK (49) PGNY (77) CCEL (64) ⌘ Pro Terminal →

Viemed Healthcare Inc. (VMD) — RQD Stock Rating Cockpit

$9.95 -0.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.92

Viemed Healthcare Inc. (VMD) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $379.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.92 (-0.26%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 4.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY • 57.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+4.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VMD)Realized 20D OHLCV Swing Band: ±5.8%

Deterministic 5-Pillar Attribution (69/100 Composite)

🔍 WHY VMD SCORES 69/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (26% of score)

Altman Z-Score 6.59 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 4.4% FCF Margin ($11.9M FCF) & 57.5% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$9.52-0.4% Next Q

Q2 (-2Q)

Grade C+$9.48+3.4% Next Q

Q3 (-1Q)

Grade B-$9.80+1.5% Next Q

Current

Grade C+$9.95+2% Hist 90D α

Trajectory: C (61) → C+ (69)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the VMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 69/100 (C+) score, VMD faces multiple-compression risk if 24.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 55.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.23) or 200D SMA ($9.57) invalidates the momentum regime and cuts Target Base ($10.44) toward Bear Floor ($8.14).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 69%NO 31%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

53.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

6.59>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

9 / 99-Pt Accounting

52-WEEK LASER RANGE59% OF RANGE

L: $6$9.95H: $13

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (58% profit margin and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 23 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 30 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on VMD

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (80)

13.0% ROIC with 57.5% gross margin and 3.15% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (90)

Altman-Z 6.59 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (58)

23/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like VMD

✓Strong cash generator (58% profit margin)—profits are backed by real money, not accounting tricks.
✓Company leadership has skin in the game with net positive insider conviction.
✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (VMD Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -0.10%▲ RESISTANCE BREAKOUT

2026-10-30O $10.00H $10.02L $9.63C $9.95VOL 119.5K

RES: $8.88SUP: $8.62SMA50: $9.23SMA200: $9.57

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VMD Butterfly Map → + Track VMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

18.3%/yr Implied 5Y Growth

vs. +20.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VMD)

Health Care Rank #103 of 1016 ⚔️ AGL vs VMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VMD vs. AGL, PARK, PGNY, CCEL)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Viemed Healthcare Inc. (VMD) ranks #103 by composite RQD confidence (69/100, grade C+) and #487 by equity capitalization ($379.0M). Within this direct 5-issuer industry benchmark cohort, VMD leads on earnings valuation at 24.6x trailing P/E, while CCEL leads on capital efficiency and profitability with 18.2% ROIC and — gross margin. PGNY currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with VMD at 69/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VMD ACTIVE Viemed Healthcare Inc.	C+	69/100	24.6x	57.5%	13.0%	-0.40%	$379.0M	Benchmark Subject
AGL agilon health inc.	E	28/100	—	—	-35.0%	-5.56%	$1.44B	/agl-vs-vmd →
PARK Park Dental Partners Inc.	D	49/100	—	—	—	-2.79%	$95.4M	/park-vs-vmd →
PGNY Progyny Inc.	B+	77/100	37.2x	23.6%	16.7%	+1.90%	$2.18B	/pgny-vs-vmd →
CCEL Cryo-Cell International Inc.	C	64/100	—	—	18.2%	+1.17%	$41.8M	/ccel-vs-vmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001729149

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Viemed Healthcare Inc. (VMD) reported GAAP revenue of $270.3M (+20.5% vs. FY2024 revenue of $224.3M , and +47.7% cumulative change since FY2023) , GAAP net income of $15.4M, operating cash flow of $51.9M, and free cash flow of $11.9M (+805.2% YoY). On the balance sheet, VMD closed FY2025 with $199.2M in total assets against $11.3M in total debt (Altman Z-Score: 6.59, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$270.3M	$15.4M	$51.9M	$11.9M	$199.2M	$11.3M
FY2024 (FY)	2024-12-31	$224.3M	$11.4M	$39.1M	$1.3M	$177.1M	$3.6M
FY2023 (FY)	2023-12-31	$183.0M	$10.2M	$45.2M	$45.2M	—	—

3. VMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Viemed Healthcare Inc. (NASDAQ: VMD) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $9.95 (-0.40% 1D, market cap $379.0M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, VMD ranks #103 in composite RQD confidence.

How does VMD compare to AGL and PARK in the Health Care sector?

Within the Health Care sector (Misc Health and Biotechnology Services), VMD carries a Roarable C+ (69/100 RQD), trailing P/E of 24.6x, gross margin of 57.5%, and ROIC of 13.0%. By comparison, AGL (agilon health inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $1.44B) and PARK (Park Dental Partners Inc.) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $95.4M). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VMD?

Per VMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001729149), Viemed Healthcare Inc. generated $270.3M in revenue (+20.5% YoY), $15.4M in net income, and $11.9M in free cash flow against $199.2M in total assets and $11.3M in total debt. Key quantitative strengths: Strong cash generator (58% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VMD trading relative to its 50-day, 200-day, and 52-week technical levels?

VMD last traded at $9.95 (-0.40% on volume of 227,278 shares), positioning the stock +7.80% above its 50-day simple moving average ($9.23) and +3.97% above its 200-day simple moving average ($9.57). Across its 52-week range of $6.05 to $12.61, VMD sits at the 59.5% percentile with a 14-day RSI of 53.1 (NEUTRAL RANGE) and an implied next-earnings move of ±5.8% ($9.37 to $10.53).

VMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell VMD stock right now?

Viemed Healthcare Inc. (VMD) currently earns a Roarable Rating of C+ (Hold — HOLD) with 69/100 RQD Confidence. Solid 58% profit margin (13% return on capital), mixed timing at 25x P/E—hold if owned, no rush to chase.

What is VMD's 12-month price target and RQD AI Jury consensus?

VMD's 12-month base price target is $10.44 (range $8.14 to $13.24), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: VMD RQD Cockpit VMD 12M Forecast VMD Earnings & Move VMD Dividends & DRIP VMD Insiders & 13F VMD Whale Options VMD Profit Sankey VMD News & Why